DK478786A - Cystein-forarmede muteiner af biologisk aktive humantumornekrosefaktorproteiner - Google Patents

Cystein-forarmede muteiner af biologisk aktive humantumornekrosefaktorproteiner Download PDF

Info

Publication number
DK478786A
DK478786A DK478786A DK478786A DK478786A DK 478786 A DK478786 A DK 478786A DK 478786 A DK478786 A DK 478786A DK 478786 A DK478786 A DK 478786A DK 478786 A DK478786 A DK 478786A
Authority
DK
Denmark
Prior art keywords
muteins
necrocess
cystein
biologically active
human tumor
Prior art date
Application number
DK478786A
Other languages
English (en)
Other versions
DK478786D0 (da
DK172276B1 (da
Inventor
David F Mark
Leo S Lin
Shi-Da Yu Lu
Alice M Wang
Original Assignee
Cetus Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24807256&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK478786(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cetus Corp filed Critical Cetus Corp
Publication of DK478786D0 publication Critical patent/DK478786D0/da
Publication of DK478786A publication Critical patent/DK478786A/da
Application granted granted Critical
Publication of DK172276B1 publication Critical patent/DK172276B1/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
DK478786A 1985-02-07 1986-10-07 Rekombinant derivat af human tumornekrosefaktor (hTNF), strukturelt gen, som koder for det rekombinante derivat, ekspressionsvektor, værtsceller, transformeret E. coli, fremgangsmåder til fremstilling af det rekombinante derivat og det strukturelle gen, oligonukleotid til brug ved fremstilling af genet, terapeutiske sammensætninger og formuleringer DK172276B1 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US69893985 1985-02-07
US06/698,939 US4959314A (en) 1984-11-09 1985-02-07 Cysteine-depleted muteins of biologically active proteins
PCT/US1986/000236 WO1986004606A1 (en) 1985-02-07 1986-02-03 Cysteine-depleted muteins of biologically active human tumor necrosis factor proteins
US8600236 1986-02-03

Publications (3)

Publication Number Publication Date
DK478786D0 DK478786D0 (da) 1986-10-07
DK478786A true DK478786A (da) 1986-12-08
DK172276B1 DK172276B1 (da) 1998-02-16

Family

ID=24807256

Family Applications (1)

Application Number Title Priority Date Filing Date
DK478786A DK172276B1 (da) 1985-02-07 1986-10-07 Rekombinant derivat af human tumornekrosefaktor (hTNF), strukturelt gen, som koder for det rekombinante derivat, ekspressionsvektor, værtsceller, transformeret E. coli, fremgangsmåder til fremstilling af det rekombinante derivat og det strukturelle gen, oligonukleotid til brug ved fremstilling af genet, terapeutiske sammensætninger og formuleringer

Country Status (8)

Country Link
US (1) US4959314A (da)
EP (1) EP0213175B1 (da)
JP (1) JPS62501608A (da)
AU (1) AU5518086A (da)
DE (1) DE3672924D1 (da)
DK (1) DK172276B1 (da)
FI (1) FI99015C (da)
WO (1) WO1986004606A1 (da)

Families Citing this family (238)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI82266C (fi) * 1982-10-19 1991-02-11 Cetus Corp Foerfarande foer framstaellning av il-2 -mutein.
US5288852A (en) * 1984-03-06 1994-02-22 Dainippon Pharmaceutical Co., Ltd. Human tumor necrosis factor polypeptides
US6107465A (en) * 1984-12-21 2000-08-22 Otsuka Pharmaceutical Co., Ltd. IL-1β and derivatives thereof and drugs
US5342614A (en) * 1984-12-21 1994-08-30 Otsuka Pharmaceutical Co., Ltd. Method of treating arthritus or inflammation with IL-1β or derivatives thereof
US5516896A (en) * 1985-02-25 1996-05-14 Zymogenetics, Inc. Biologically active B-chain homodimers
US5244806A (en) * 1985-08-26 1993-09-14 Eli Lilly And Company DNA encoding novel tissue plasminogen activator derivatives having kringles 1 and 2 deleted, vectors and host cells
US5859208A (en) * 1988-07-06 1999-01-12 Fiddes; John C. Human basic fibroblast growth factor analog
DE3750915T2 (de) * 1986-02-04 1995-08-24 Den Ichi Mizuno Für Antitumor-Polypeptide kodierende DNS, die Polypeptide und diese Polypeptide enthaltenden Antitumor-Wirkstoffe.
US5008374A (en) * 1986-03-14 1991-04-16 Otsuka Pharmaceutical Co., Ltd. IL-1α derivatives and drugs
US5900476A (en) * 1986-05-30 1999-05-04 The Scripps Research Institute Therapeutic domains of van Willebrand factor
DE3750106T3 (de) * 1986-08-06 1999-04-22 Ajinomoto Kk Rekombinanter B-Zell-Differenzierungsfaktor.
US5681934A (en) * 1986-09-30 1997-10-28 Board Of Regents, The University Of Texas System 47-kilodalton antigen of Treponema pallidum
US7049131B1 (en) * 1987-02-12 2006-05-23 Genentech, Inc. Methods and deoxyribonucleic acid for the preparation of tissue factor protein
US6994988B1 (en) 1987-02-12 2006-02-07 Genetech, Inc. Methods and deoxyribonucleic acid for the preparation of tissue factor protein
US5852177A (en) * 1987-02-24 1998-12-22 Takeda Chemical Industries, Ltd. Basic fibroblast growth factor (bFGF) muteins
AU1346488A (en) * 1987-02-26 1988-09-26 Cetus Corporation Arginine-depleted human tumor necrosis factor
ZA884012B (en) * 1987-06-04 1989-02-22 Zymogenetics Inc Tissue plasminogen activator analogs having modified growth factor domains
EP0355460B1 (en) * 1988-08-24 2000-12-27 American Cyanamid Company Stabilization of somatotropins by modification of cysteine residues utilizing site directed mutagenesis or chemical derivatization
DE3907244A1 (de) * 1989-03-07 1990-09-13 Knoll Ag Erzeugnisse, enthaltend ein lithiumsalz und einen tumor-nekrose-faktor
US5621078A (en) * 1989-03-22 1997-04-15 Merck & Co., Inc. Modified pseudomonas exotoxin PE40
WO1990012877A1 (en) * 1989-04-19 1990-11-01 Cetus Corporation Multifunctional m-csf proteins and genes encoding therefor
US6207798B1 (en) * 1989-08-03 2001-03-27 Merck & Co., Inc. Modified PE40 toxin fusion proteins
FR2651130B1 (fr) * 1989-08-23 1991-12-13 Roussel Uclaf Sequence d'oligonucleotides anti-sens, anti-arn message du tnf alpha, procede de preparation, application a titre de medicaments et compositions pharmaceutiques.
WO1991005798A1 (en) * 1989-10-10 1991-05-02 Amgen Inc. Compositions and methods for treating or preventing infections in canine and feline animals
GEP20033145B (en) * 1989-10-16 2003-12-25 Amgen Inc Stem Cell Factor
US20040181044A1 (en) * 1989-10-16 2004-09-16 Zsebo Krisztina M. Method of stimulating growth of epithelial cells by administering stem cell factor
US7144731B2 (en) 1989-10-16 2006-12-05 Amgen Inc. SCF antibody compositions and methods of using the same
US6852313B1 (en) 1989-10-16 2005-02-08 Amgen Inc. Method of stimulating growth of melanocyte cells by administering stem cell factor
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
US6566098B1 (en) * 1990-09-14 2003-05-20 The United States Of America As Represented By The Department Of Health And Human Services DNA encoding truncated hepatocyte growth factor variants
EP0477791B1 (en) * 1990-09-21 1996-08-07 Ishihara Sangyo Kaisha, Ltd. Polypeptide
JPH05255393A (ja) * 1990-09-21 1993-10-05 Ishihara Sangyo Kaisha Ltd ポリペプチド
DE69119869T2 (de) * 1990-11-23 1996-12-12 American Cyanamid Co Chimeres Fibroblasten-Wachstumsfaktor
US6833354B1 (en) * 1990-12-19 2004-12-21 Kaken Pharmaceutical Co., Ltd. Agent for the treatment of bone diseases
EP0648268A1 (en) * 1991-03-27 1995-04-19 The Scripps Research Institute Therapeutic fragments of von willebrand factor
JP3303211B2 (ja) * 1991-04-26 2002-07-15 武田薬品工業株式会社 ｂＦＧＦムテインおよびその製造法
EP0590048B1 (en) * 1991-06-20 2004-12-01 Aventis Behring L.L.C. A process for preparing therapeutic fragments of von willebrand factor
US5847086A (en) * 1991-06-20 1998-12-08 Centeon L.L.C. Therapeutic fragments of von Willebrand factor
ZA924674B (en) * 1991-07-02 1993-04-28 Imclone Systems Inc Cysteine depleted il-6 mutein
US5248604A (en) * 1991-07-22 1993-09-28 Bio-Technology General Corp. Enzymatically active recombinant human acetylcholinesterase and hosts and vectors for expression thereof
FR2686899B1 (fr) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
GB9204439D0 (en) * 1992-02-27 1992-04-15 Fujisawa Pharmaceutical Co A new cephalosporin c acylase
US5326695A (en) * 1992-05-15 1994-07-05 Ludwig Institute For Cancer Research Platelet derived growth factor agonists
US5444151A (en) * 1992-05-15 1995-08-22 Ludwig Institute For Cancer Research Platelet derived growth factor antagonists
US5349056A (en) * 1992-10-09 1994-09-20 Regeneron Pharmaceuticals Modified ciliary neurotrophic factors
US5420019A (en) * 1993-02-02 1995-05-30 Xoma Corporation Stable bactericidal/permeability-increasing protein muteins
US7060484B1 (en) 1993-11-12 2006-06-13 Gilead Sciences, Inc. Polypeptides and coagulation therapy
EP0728210B1 (en) * 1993-11-12 2005-04-13 Gilead Sciences, Inc. Thrombin mutants
US20030220233A1 (en) 1994-01-24 2003-11-27 Neorx Corporation Radiolabeled annexins
US5968477A (en) * 1994-01-24 1999-10-19 Neorx Corporation Radiolabeled annexin conjugates with hexose and a chelator
US5545723A (en) * 1994-03-15 1996-08-13 Biogen Inc. Muteins of IFN-β
SI0804479T1 (sl) * 1994-10-13 2006-12-31 Amgen Inc Metoda zdravljenja sladkorne bolezni z uporabo kgf
US6130071A (en) * 1997-02-05 2000-10-10 Helsinki University Licensing, Ltd. Vascular endothelial growth factor C (VEGF-C) ΔCys156 protein and gene, and uses thereof
US6645933B1 (en) 1995-08-01 2003-11-11 Helsinki University Licensing Ltd. Oy Receptor ligand VEGF-C
US6818220B1 (en) 1994-11-14 2004-11-16 Licentia Ltd. Vascular endothelial growth factor C (VEGF-C) protein and gene mutants thereof, and uses thereof
IL114615A0 (en) 1995-07-16 1995-11-27 Yeda Res & Dev Modulators of the function of fas receptors and other proteins
IL117175A (en) * 1995-02-20 2005-11-20 Sankyo Co Osteoclastogenesis inhibitory factor protein
US7727761B2 (en) 1995-08-01 2010-06-01 Vegenics Limited Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof
US6361946B1 (en) 1997-02-05 2002-03-26 Licentia Ltd Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof
US20030202980A1 (en) * 1995-12-29 2003-10-30 Caplan Michael J. Methods and reagents for decreasing clinical reaction to allergy
GB9526733D0 (en) * 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
TW555765B (en) 1996-07-09 2003-10-01 Amgen Inc Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
US6743422B1 (en) 1996-10-15 2004-06-01 Amgen, Inc. Keratinocyte growth factor-2 products
US20030144202A1 (en) * 1996-10-15 2003-07-31 Amgen Inc. Uses of keratinocyte growth factor-2
PT942740E (pt) 1996-12-06 2004-01-30 Amgen Inc Terapia de combinacao utilizando uma proteina de ligacao de tnf para tratamento de doencas mediadas por tnf
EP2371962A3 (en) 1996-12-23 2011-12-21 Immunex Corporation Receptor activator of NF-KAPPA B, receptor is member of TNF receptor superfamily
EP0966480A2 (en) 1997-01-30 1999-12-29 The University Of Virginia Patent Foundation Cysteine-depleted peptides recognized by a3-restricted cytotoxic lymphocytes, and uses therefor
US7125714B2 (en) * 1997-02-05 2006-10-24 Licentia Ltd. Progenitor cell materials and methods
ATE328006T1 (de) * 1997-04-15 2006-06-15 Sankyo Co Neues protein und verfahren zu dessen herstellung
CZ302262B6 (cs) 1997-04-16 2011-01-19 Amgen Inc. Izolovaná nukleová kyselina, polypeptid kódovaný touto nukleovou kyselinou, expresní vektor obsahující tuto nukleovou kyselinu, hostitelská bunka transfekovaná tímto expresním vektorem, izolovaný protein vázající osteoprotegerin, protilátka vázající
US6316408B1 (en) * 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
AU7383298A (en) * 1997-05-13 1998-12-08 Regents Of The University Of California, The Novel antiangiogenic peptide agents and their therapeutic and diagnostic use
US7723473B2 (en) * 1997-06-19 2010-05-25 St. Louis University Peptide antagonists of TGF-beta family members and therapeutic uses thereof
CA2315251A1 (en) * 1997-12-17 1999-06-24 Immunex Corporation Cell surface glycoproteins associated with human b cell lymphomas - ulbp, dna and polypeptides
US8101349B2 (en) 1997-12-23 2012-01-24 Novartis Vaccines And Diagnostics, Inc. Gene products differentially expressed in cancerous cells and their methods of use II
US7879977B2 (en) 1998-01-31 2011-02-01 University Of Arkansas Methods and reagents for decreasing clinical reaction to allergy
CA2319437C (en) 1998-01-31 2009-06-16 University Of Arkansas Methods and reagents for decreasing allergic reactions
US6955807B1 (en) 1998-05-15 2005-10-18 Bayer Pharmaceuticals Corporation IL-2 selective agonists and antagonists
US6476211B1 (en) * 1998-07-16 2002-11-05 Hyseq, Inc. Methods and materials relating to CD39-like polypeptides
IL140931A0 (en) * 1998-07-16 2002-02-10 Hyseq Inc Methods and materials relating to novel cd39-like polypeptides
US6387645B1 (en) 1998-07-16 2002-05-14 Hyseq, Inc. Methods and materials relating to novel CD39-like polypeptides
US6447771B1 (en) 1999-03-19 2002-09-10 Hyseq, Inc. Methods and materials relating to novel CD39-like polypeptides
US6979442B1 (en) 1998-08-17 2005-12-27 Pfizer Inc. Stabilized protein compositions
EP2123292B1 (en) 1998-09-03 2016-05-04 Novartis Vaccines and Diagnostics, Inc. Angiogenically effective unit dose of FGF-2 and method of use
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US6696063B1 (en) * 1998-12-30 2004-02-24 Applied Research Systems Ars Holding N.V. Treatment of HIV-associated dysmorphia/dysmetabolic syndrome (HADDS) with or without lipodystrophy
US7625859B1 (en) * 2000-02-16 2009-12-01 Oregon Health & Science University HER-2 binding antagonists
US7393823B1 (en) 1999-01-20 2008-07-01 Oregon Health And Science University HER-2 binding antagonists
US6350447B1 (en) 1999-01-29 2002-02-26 Hyseq, Inc. Methods and compositions relating to CD39-like polypeptides and nucleic acids
US6899875B1 (en) 1999-01-29 2005-05-31 Nuvelo, Inc. Methods and compositions relating to CD39-like polypeptides and nucleic acids
US6783959B1 (en) 1999-01-29 2004-08-31 Nuvelo, Inc. Methods and compositions relating to CD39-like polypeptides and nucleic acids
US6780977B1 (en) 1999-01-29 2004-08-24 Nuvelo, Inc. Methods and compositions relating to CD39-like polypeptides and nucleic acids
US6335013B1 (en) 1999-03-19 2002-01-01 Hyseq, Inc. Methods and materials relating to CD39-like polypeptides
AU4338100A (en) * 1999-04-09 2000-11-14 Chiron Corporation Secreted human proteins
US6514729B1 (en) 1999-05-12 2003-02-04 Xencor, Inc. Recombinant interferon-beta muteins
US6703221B1 (en) 1999-08-19 2004-03-09 Chiron Corporation Notch receptor ligands and uses thereof
US6825333B1 (en) 1999-08-20 2004-11-30 Chiron Corporation EGFH2 genes and gene products
IL150109A0 (en) * 1999-12-09 2002-12-01 Chiron Corp Method for administering a cytokine to the central nervous system and the lymphatic system
US20030103978A1 (en) * 2000-02-23 2003-06-05 Amgen Inc. Selective binding agents of osteoprotegerin binding protein
US8246945B2 (en) * 2000-04-06 2012-08-21 University Of Arkansas Methods and reagents for decreasing clinical reaction to allergy
DK1272213T3 (da) * 2000-04-06 2006-07-10 Seer Pharmaceuticals Llc Mikrobielt afgivelsessystem
US20050063994A1 (en) * 2000-04-06 2005-03-24 Caplan Michael J. Methods and reagents for decreasing clinical reaction to allergy
US6946134B1 (en) 2000-04-12 2005-09-20 Human Genome Sciences, Inc. Albumin fusion proteins
JP2003531590A (ja) 2000-04-12 2003-10-28 ヒューマン ゲノム サイエンシズ インコーポレイテッド アルブミン融合タンパク質
WO2001085208A2 (en) * 2000-05-05 2001-11-15 Cytos Biotechnology Ag Molecular antigen arrays and vaccines
US7700359B2 (en) * 2000-06-02 2010-04-20 Novartis Vaccines And Diagnostics, Inc. Gene products differentially expressed in cancerous cells
EP1953243B1 (en) 2000-06-15 2012-12-26 Novartis Vaccines and Diagnostics, Inc. Polynucleotides related to colon cancer
FR2811323B1 (fr) * 2000-07-07 2006-10-06 Fuma Tech Gmbh Materiau hybride, utilisation dudit materiau hybride et procede de sa fabrication
CA2415690A1 (en) * 2000-07-14 2002-01-24 Chiron Corporation Tetraspan protein and uses thereof
EP1415005B1 (en) 2000-12-07 2012-11-21 Novartis Vaccines and Diagnostics, Inc. Endogenous retroviruses up-regulated in prostate cancer
US20020155473A1 (en) * 2000-12-22 2002-10-24 Zaoyuan Peng Methods for identifying G-protein coupled receptors associated with diseases
US7094409B2 (en) * 2001-01-19 2006-08-22 Cytos Biotechnology Ag Antigen arrays for treatment of allergic eosinophilic diseases
WO2002059337A1 (en) * 2001-01-26 2002-08-01 Georgetown University School Of Medicine Anti-apoptopic gene scc-s2 and diagnostic and therapeutic uses thereof
WO2002081641A2 (en) * 2001-04-06 2002-10-17 Georgetown University Gene scc-112 and diagnostic and therapeutic uses thereof
AU2002303262A1 (en) * 2001-04-06 2002-10-21 Georgetown University Gene shinc-1 and diagnostic and therapeutic uses thereof
WO2002081639A2 (en) * 2001-04-06 2002-10-17 Georgetown University Gene brcc2 and diagnostic and therapeutic uses thereof
AU2002258728A1 (en) 2001-04-06 2002-10-21 Georgetown University Gene brcc-3 and diagnostic and therapeutic uses thereof
US6887462B2 (en) 2001-04-09 2005-05-03 Chiron Corporation HSA-free formulations of interferon-beta
US20060084794A1 (en) * 2001-04-12 2006-04-20 Human Genome Sciences, Inc. Albumin fusion proteins
US20050244931A1 (en) * 2001-04-12 2005-11-03 Human Genome Sciences, Inc. Albumin fusion proteins
US20050054051A1 (en) * 2001-04-12 2005-03-10 Human Genome Sciences, Inc. Albumin fusion proteins
US7507413B2 (en) 2001-04-12 2009-03-24 Human Genome Sciences, Inc. Albumin fusion proteins
ES2356934T3 (es) 2001-06-05 2011-04-14 Curevac Gmbh ARNm ESTABILIZADO CON UN CONTENIDO DE G/C AUMENTADO QUE CODIFICA PARA UN ANTÍGENO VIRAL.
JP2005507870A (ja) * 2001-08-13 2005-03-24 ユニバーシティ・オブ・サザン・カリフォルニア 低毒性のインターロイキン−２突然変異体
US20070020622A1 (en) * 2001-09-14 2007-01-25 Invitrogen Corporation DNA Polymerases and mutants thereof
WO2003030821A2 (en) * 2001-10-05 2003-04-17 Human Genome Sciences, Inc. Albumin fusion proteins
US20040126762A1 (en) * 2002-12-17 2004-07-01 Morris David W. Novel compositions and methods in cancer
US20040166490A1 (en) * 2002-12-17 2004-08-26 Morris David W. Novel therapeutic targets in cancer
US20060040262A1 (en) * 2002-12-27 2006-02-23 Morris David W Novel compositions and methods in cancer
US20040180344A1 (en) * 2003-03-14 2004-09-16 Morris David W. Novel therapeutic targets in cancer
US20040197778A1 (en) * 2002-12-26 2004-10-07 Sagres Discovery, Inc. Novel compositions and methods in cancer
JP4822490B2 (ja) * 2001-12-07 2011-11-24 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 腫瘍形成形質転換に関連する内因性レトロウイルスポリペプチド
US20060275747A1 (en) * 2001-12-07 2006-12-07 Hardy Stephen F Endogenous retrovirus up-regulated in prostate cancer
DE10162480A1 (de) 2001-12-19 2003-08-07 Ingmar Hoerr Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen
EP1997829A1 (en) 2001-12-21 2008-12-03 Human Genome Sciences, Inc. Albumin fusion proteins
IL147414A0 (en) * 2001-12-31 2002-08-14 Yeda Res & Dev Ifnar2 mutants, their production and use
WO2003080808A2 (en) * 2002-03-21 2003-10-02 Sagres Discovery, Inc. Novel compositions and methods in cancer
MXPA04009681A (es) * 2002-04-05 2005-01-11 Amgen Inc Anticuerpos humanos neutralizantes anti-ligando de osteoprotegerina como inhibidores selectivos de la ruta del ligando de osteoprotegerina.
JP4430403B2 (ja) * 2002-04-10 2010-03-10 メルク セローノ ソシエテ アノニム 線維化疾患の治療および／または予防のためのオステオプロテゲリンの使用
US7585840B2 (en) 2002-04-10 2009-09-08 Merck Serono S.A. Use of osteoprotegerin for the treatment and/or prevention of fibrotic disease
US7138512B2 (en) * 2002-04-10 2006-11-21 Georgetown University Gene SHINC-2 and diagnostic and therapeutic uses thereof
US7244565B2 (en) * 2002-04-10 2007-07-17 Georgetown University Gene shinc-3 and diagnostic and therapeutic uses thereof
US20030228317A1 (en) * 2002-05-22 2003-12-11 Prafulla Gokhale Gene BRCC-1 and diagnostic and therapeutic uses thereof
TWI334785B (en) * 2002-06-03 2010-12-21 Serono Lab Use of recombinant ifn-β1a and pharmaceutical composition comprising recombinant ifn-β1a for the treatment of hcv infection in patients of asian race
JP2005535308A (ja) * 2002-06-13 2005-11-24 カイロン コーポレイション Ｈｍｌ−２ポリペプチド発現用ベクター
AU2003248845A1 (en) * 2002-07-12 2004-02-02 The Regents Of The University Of California Steroidogenic factor-1 protein variants and methods of making same
SI1524994T1 (sl) * 2002-07-19 2011-08-31 Cytos Biotechnology Ag Sestavki cepiv, ki vsebujejo amiloidne beta 1-6 antigenske mreĹľe
US20040175359A1 (en) * 2002-11-12 2004-09-09 Desjarlais John Rudolph Novel proteins with antiviral, antineoplastic, and/or immunomodulatory activity
CA2513213C (en) 2003-01-22 2013-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
US7767387B2 (en) * 2003-06-13 2010-08-03 Sagres Discovery, Inc. Therapeutic targets in cancer
US20070218071A1 (en) * 2003-09-15 2007-09-20 Morris David W Novel therapeutic targets in cancer
US20040170982A1 (en) 2003-02-14 2004-09-02 Morris David W. Novel therapeutic targets in cancer
EP1606398A1 (en) * 2003-03-26 2005-12-21 Cytos Biotechnology AG Melan-a peptide analogue-virus-like-particle conjugates
US7537767B2 (en) * 2003-03-26 2009-05-26 Cytis Biotechnology Ag Melan-A- carrier conjugates
US20060210588A1 (en) * 2003-03-26 2006-09-21 Cytos Biotechnology Ag Hiv-peptide-carrier-conjugates
JP4865540B2 (ja) 2003-04-08 2012-02-01 イエダ リサーチ アンド ディベロップメント カンパニー リミテッド 化学誘引物質に対する増大された感受性を有する幹細胞およびそれを産生および使用する方法
FR2853551B1 (fr) 2003-04-09 2006-08-04 Lab Francais Du Fractionnement Formulation stabilisante pour compositions d'immunoglobulines g sous forme liquide et sous forme lyophilisee
TWI272948B (en) 2003-05-01 2007-02-11 Ares Trading Sa HSA-free stabilized interferon liquid formulations
US20070281896A1 (en) * 2003-09-30 2007-12-06 Morris David W Novel compositions and methods in cancer
IL158287A0 (en) 2003-10-07 2004-05-12 Yeda Res & Dev Antibodies to nik, their preparation and use
IL158868A0 (en) * 2003-11-13 2004-05-12 Yeda Res & Dev Methods of generating and using stem cells enriched with immature primitive progenitor
DE102004008168B4 (de) * 2004-02-19 2015-12-10 Voxeljet Ag Verfahren und Vorrichtung zum Auftragen von Fluiden und Verwendung der Vorrichtung
WO2005084303A2 (en) * 2004-03-01 2005-09-15 Enzon Pharmaceuticals, Inc. Interferon-beta polymer conjugates
IL161673A0 (en) 2004-04-29 2004-09-27 Applied Research Systems Compositions and methods for therapy of chemotherapy-induced neuropathy
AU2005244448B2 (en) * 2004-05-17 2011-03-17 Ares Trading S.A. Hydrogel interferon formulations
BRPI0510526A (pt) * 2004-06-01 2007-10-30 Ares Trading Sa formulações lìquidas estabilizadas de interferon
ES2381674T3 (es) 2004-06-01 2012-05-30 Ares Trading S.A. Método de estabilizar proteínas
US20060024677A1 (en) 2004-07-20 2006-02-02 Morris David W Novel therapeutic targets in cancer
DE102004042546A1 (de) 2004-09-02 2006-03-09 Curevac Gmbh Kombinationstherapie zur Immunstimulation
CA2583230A1 (en) * 2004-10-05 2006-04-20 Oregon Health And Science University Compositions and methods for treating disease
GB0424563D0 (en) * 2004-11-05 2004-12-08 Novartis Ag Organic compounds
PT1809662E (pt) * 2004-11-10 2009-02-26 Novartis Vaccines & Diagnostic Interferão beta desamidado
TW200633718A (en) * 2004-12-16 2006-10-01 Applied Research Systems Treatment of hepatitis c in the asian population
EP1865981A2 (en) 2005-04-07 2007-12-19 Chiron Corporation Cacna1e in cancer diagnosis, detection and treatment
WO2006110585A2 (en) 2005-04-07 2006-10-19 Novartis Vaccines And Diagnostics Inc. Cancer-related genes (prlr)
US20060242012A1 (en) * 2005-04-22 2006-10-26 Sumit Agarwal Determining or scoring properties to solicit to join ad network using advertiser or aggregated advertiser interest
AU2006239405B2 (en) 2005-04-26 2011-12-08 Merck Serono Sa INSP163 polypeptides for the treatment or prevention of cancer and arthritis
US8076102B2 (en) 2005-05-18 2011-12-13 Biofactura, Inc. Compositions and methods for metabolic selection of transfected cells
US20070179113A1 (en) * 2005-05-19 2007-08-02 Schering Aktiengesellachaft GM-CSF gene therapy for Crohn's disease using an improved regulated expression system
US20080076729A1 (en) * 2005-05-19 2008-03-27 Schering Aktiengesellachaft Interferon-beta gene therapy using an improved, regulated expression system
TW200724679A (en) * 2005-05-19 2007-07-01 Schering Ag Treatment of disease using an improved regulated expression system
AR053284A1 (es) * 2005-05-19 2007-04-25 Schering Ag Terapia genica de interferon -beta usando un sistema mejorado de expresion regulada
ATE517917T1 (de) 2005-06-03 2011-08-15 Ares Trading Sa Herstellung eines rekombinanten il-18-bindenden proteins
SI1891088T1 (sl) * 2005-06-10 2012-02-29 Ares Trading Sa Postopek za äśiĺ äśenje il-18 vezavnega proteina
EP1904092A4 (en) * 2005-07-21 2011-08-17 Buck Inst For Age Res FIBROBLAST GROWTH FACTOR-2 PROMOTES NEUROGENESIS AND NERVE PROTECTION AND EXTENDS THE LIFE OF HUNTINGTON DISEASE
US20070026463A1 (en) * 2005-07-28 2007-02-01 Wyeth Compositions and methods of mutant Nogo-66 domain proteins
RU2008107150A (ru) * 2005-07-29 2009-09-10 Новартис Аг, (Ch) Способ и система для сворачивания белка ин витро
EP1760092A1 (en) 2005-08-26 2007-03-07 Applied Research Systems ARS Holding N.V. System for screening cells for high expression of a protein of interest
WO2007022799A1 (en) 2005-08-26 2007-03-01 Ares Trading S.A. Process for the preparation of glycosylated interferon beta
KR20080050591A (ko) * 2005-09-01 2008-06-09 아레스 트레이딩 에스.에이. 시신경염 치료
EP2045265B1 (en) 2005-09-22 2012-11-21 Biocompatibles Uk Ltd. GLP-1 (Glucagon-like peptide-1) fusion polypeptides with increased peptidase resistance
WO2007135172A2 (en) 2006-05-24 2007-11-29 Laboratoires Serono S.A. Cladribine regimen for treating multiple sclerosis
CA2839595A1 (en) 2006-06-28 2008-01-03 Yeda Research And Development Co. Ltd. Caspase-8 and inflammation, infection and wound healing
US9131648B2 (en) * 2006-07-07 2015-09-15 Washington State University Genes encoding chavicol/eugenol synthase from the creosote bush Larrea tridentata
EP2469283B1 (en) * 2006-09-08 2014-01-15 The Chancellor, Masters and Scholars of the University of Oxford Clinical diagnosis of hepatic fibrosis using human serum APOL1 as biomarker
KR20090104041A (ko) * 2006-12-19 2009-10-05 메리맥 파마슈티컬즈, 인크. 다발성 경화증을 치료하기 위한 α페토프로테인 및 면역조절제의 병용투여
WO2008125222A2 (en) * 2007-04-11 2008-10-23 Bayer Schering Pharma Aktiengesellschaft New modulation molecules for an improved regulated expression system
BRPI0810622A2 (pt) * 2007-05-02 2020-10-13 Ambrx, Inc. polipeptídeos de interferon beta modificados e seus usos
WO2009029656A1 (en) * 2007-08-27 2009-03-05 Auxagen, Inc. METHODS FOR INHIBITING TGF-β
US8273561B2 (en) * 2007-10-05 2012-09-25 Nuron Biotech, Inc. High pressure treatment of aggregated interferons
EA201070773A1 (ru) * 2007-12-20 2010-12-30 Мерк Сероно С. А. Составы пэг-интерферона-бета
IL189408A0 (en) 2008-02-10 2009-02-11 Yeda Res & Dev Siva3, its preparation and pharmaceutical compositions containing it
EA020628B1 (ru) 2008-03-04 2014-12-30 Вашингтон Стейт Юниверсити Композиции и способы для дифференциальной регуляции ненасыщенности жирных кислот в мембранных липидах и масле семян
AU2009234253C1 (en) 2008-04-11 2015-05-07 Merrimack Pharmaceuticals, Inc. Human serum albumin linkers and conjugates thereof
JP5773366B2 (ja) 2008-04-21 2015-09-02 ティシュー リジェネレイション セラピューティックス、インコーポレイテッド 生物学的又は化学的作用物質に対する予防又はそれらの治療のために遺伝子改変されたヒト臍帯血管周囲細胞
US8487006B2 (en) * 2008-09-16 2013-07-16 Auxagen, Inc. Method of enhancing TGF-β signalling
BRPI0921586A2 (pt) 2008-11-18 2019-09-24 Merrimack Pharmaceuticals Inc articuladores de albumina de soro humana e conjugados destes
US9074005B2 (en) * 2009-01-02 2015-07-07 Washington State University Compositions and methods for modulating plant disease resistance and immunity
CN201397956Y (zh) * 2009-03-23 2010-02-03 富士康(昆山)电脑接插件有限公司 电连接器组件
ES2527455T3 (es) * 2009-05-14 2015-01-23 The Chancellor, Masters And Scholars Of The University Of Oxford Diagnóstico clínico de fibrosis/cirrosis hepática usando biomarcadores de proteínas plasmáticas humanas poco abundantes
EP2440251A4 (en) * 2009-06-09 2013-01-16 Defyrus Inc INTERFERON ADMINISTRATION FOR PROPHYLAXIS AGAINST PATHOGEN INFECTION OR TREATMENT OF PATHOGEN INFECTION
US20110016548A1 (en) * 2009-07-16 2011-01-20 University Of Southern California Control of endogenous dnmt1 gene expression by exogenous binary regulatory systems
CU23734A1 (es) 2009-11-27 2011-11-15 Centro Inmunologia Molecular Polipéptidos inmunomoduladores derivados de la il-2 con actividad antagonista de esta citocina útiles en la terapia del cáncer y enfermedades infecciosas crónicas
WO2012019168A2 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
DK3590949T3 (da) 2010-10-01 2022-07-11 Modernatx Inc Ribonukleinsyrer indeholdende n1-methyl-pseudouracil og anvendelse heraf
CU23923B1 (es) 2010-11-12 2013-07-31 Ct De Inmunología Molecular Polipéptidos derivados de la il-2 con actividad agonista
US8710200B2 (en) 2011-03-31 2014-04-29 Moderna Therapeutics, Inc. Engineered nucleic acids encoding a modified erythropoietin and their expression
EP2694550B1 (en) 2011-04-01 2019-11-27 Universität Stuttgart Recombinant tnf ligand family member polypeptides with antibody binding domain and uses thereof
EP2709595B1 (en) 2011-05-20 2016-02-03 Ares Trading S.A. Ifn-beta compositions, preparation methods and uses thereof
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
RU2648950C2 (ru) 2011-10-03 2018-04-02 Модерна Терапьютикс, Инк. Модифицированные нуклеозиды, нуклеотиды и нуклеиновые кислоты и их применение
US20130156849A1 (en) 2011-12-16 2013-06-20 modeRNA Therapeutics Modified nucleoside, nucleotide, and nucleic acid compositions
JP6280031B2 (ja) 2012-03-29 2018-02-14 中外製薬株式会社 抗ｌａｍｐ５抗体およびその利用
WO2013151667A1 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9303079B2 (en) 2012-04-02 2016-04-05 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
WO2014036520A1 (en) 2012-08-30 2014-03-06 Merrimack Pharmaceuticals, Inc. Combination therapies comprising anti-erbb3 agents
EP2920212A4 (en) * 2012-11-15 2016-07-27 Esperance Pharmaceuticals Inc FUSION CONSTRUCTS FROM FOLLICULAR STIMULATING HORMONE (FSH) AND A LYTIC DOMAIN AND METHOD FOR THE PRODUCTION AND USE THEREOF
RS63237B1 (sr) 2012-11-26 2022-06-30 Modernatx Inc Terminalno modifikovana rnk
EP3936137A1 (en) 2013-02-07 2022-01-12 The General Hospital Corporation Methods for expansion or depletion of t-regulatory cells
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
WO2014152030A1 (en) 2013-03-15 2014-09-25 Moderna Therapeutics, Inc. Removal of dna fragments in mrna production process
KR20160067219A (ko) 2013-10-03 2016-06-13 모더나 세라퓨틱스, 인코포레이티드 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드
CA2925021A1 (en) 2013-11-01 2015-05-07 Curevac Ag Modified rna with decreased immunostimulatory properties
AU2015328163B2 (en) 2014-10-09 2020-10-15 Dana-Farber Cancer Institute, Inc. Multiple-variable IL-2 dose regimen for treating immune disorders
CN108929383B (zh) * 2017-05-26 2021-10-15 阿思科力(苏州)生物科技有限公司 重组Slit2D2(C386S)-HSA融合蛋白及其在预防和/或治疗肺部炎症中的应用
WO2023122716A1 (en) 2021-12-22 2023-06-29 Vanderbilt University Next generation transpososomes

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI82266C (fi) 1982-10-19 1991-02-11 Cetus Corp Foerfarande foer framstaellning av il-2 -mutein.
US4518584A (en) * 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
DK265384A (da) * 1983-06-01 1984-12-02 Hoffmann La Roche Polypeptider med interferonaktivitet
US4816566A (en) * 1983-06-01 1989-03-28 Hoffmann-La Roche, Inc. Polypeptides having interferon activity
CA1265444A (en) 1983-06-27 1990-02-06 Lloyd J. Old Effect of human tumor necrosis factor and human interferon on human cancer cells and methods
EP0155549B1 (en) 1984-03-06 1991-03-20 Dainippon Pharmaceutical Co., Ltd. Dna encoding human tumor necrosis factor and human tumor necrosis factor polypeptide
US4879226A (en) 1984-04-06 1989-11-07 Asahi Kasei Kogyo Kabushiki Kaisha Novel human physiologically active polypeptide
GR851626B (da) 1984-07-05 1985-11-26 Genentech Inc

Also Published As

Publication number Publication date
US4959314A (en) 1990-09-25
EP0213175A1 (en) 1987-03-11
JPS62501608A (ja) 1987-07-02
EP0213175B1 (en) 1990-07-25
FI864036A0 (fi) 1986-10-06
DK478786D0 (da) 1986-10-07
DE3672924D1 (de) 1990-08-30
FI864036A (fi) 1986-10-06
FI99015B (fi) 1997-06-13
WO1986004606A1 (en) 1986-08-14
FI99015C (fi) 1997-09-25
AU5518086A (en) 1986-08-26
DK172276B1 (da) 1998-02-16

Similar Documents

Publication Publication Date Title
DK478786A (da) Cystein-forarmede muteiner af biologisk aktive humantumornekrosefaktorproteiner
DE69229975D1 (de) Pharmazeutische Zusammensetzungen, die ein Anticytokin enthalten
DOP1981004064A (es) Interferones leucocitarios hibridos para uso en el tratamiento de enfermedades neoplasticas virales.
PT97316A (pt) Sequencias de dna,construcoes de dna e metodo para a sua aplicacao no tratamento de doencas celulares proliferativas
ES2134770T3 (es) Proteinas producidas por los linfocitos humanos, secuencia de adn codante para estas proteinas y aplicaciones farmaceuticas y biologicas.
DK163683D0 (da) Fremstilling af funktionelle humane urokinaseproteiner, dna-sekvens, der koder for et protein omfattende den enzymatiske del af human urokinase, replicerbart udtrykkelsesmedium, der kan udtrykkedna-sekvensen og mikroorganisme eller cellekultur transformeret med mediet
GT198277746A (es) Interteron inmune humano
DE68929043T2 (de) Für androgen-rezeptor-protein kodierende dna
ES2068791T1 (es) Metodos y acido desoxirribonucleico para la preparacion de proteina de factor de tejido.
ES2073327T3 (es) Gen y proteina inducida por tgf-beta.
FI900808A0 (fi) Humant mannos bindande protein.
FI90436B (fi) Ihmisen gammainterferonin kaltaisesti vaikuttavien polypeptidien valmistus
DE68925869T2 (de) Modifizierte Proteine, modifizierte Interferone alpha- und beta-phosphorylierte Proteine, DNA-Sequenzen und Analoge und deren Verwendung
ATE88500T1 (de) Dna-sequenzen, die fuer proteine mit der biologischen aktivitaet der husi-typi-inhibitoren codieren, gentechnologische verfahren zur herstellung dieser proteine und diese proteine enthaltende arzneimittel.
DK0592566T3 (da) IL-6-muteiner med reduceret cysteinantal
DE3881023D1 (de) Proteine, expressionsvektoren, die fuer solche proteine kodierende dna enthalten und zellen, die solche expressionsvektoren enthalten.
BR9712793A (pt) Fatores homólogos (fhfs) ao fator do desenvolvimento de fibroblasto e métodos de uso
ATE62490T1 (de) Verfahren zur reinigung vom humanen tumornekrosefaktor.
ATE286509T1 (de) Interferon alpha/beta bindendes protein, seine herstellung und anwendung
ATE131175T1 (de) Protein mit fibroblasten-wachstumsfaktor- rezeptoraktivität.
DK569886A (da) Fremstilling af human somatomedin c
DK595187A (da) Minactivin og fremgangsmaade til fremstilling deraf
DE59611330D1 (de) Arzneimittel enthaltend wenigstens einen teil des ul84-proteins des cytomegalovirus, verwendung von polypeptiden entsprechend der aminosäuresequenz des ul84-proteins und verfahren zur einführung von ul84 in zielzellen
DE3680140D1 (de) Behandlung von parasiterkrankungen.
ATE54941T1 (de) Cystein verminderte muteine von biologisch aktiven menschlichen tnf-proteinen.

Legal Events

Date Code Title Description
PUP Patent expired